Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698624 | 0.88 | ALDH1A1 (0.35) | ALDH1A1MAPTTDP1KMT2AFPR2 | |
| SCHEMBL697152 | 0.88 | ALDH1A1 (0.35) | ALDH1A1MAPTTDP1KMT2AFPR2 | |
| SCHEMBL3528743 | 0.88 | ALDH1A1 (0.35) | ALDH1A1MAPTTDP1KMT2AFPR2 | |
| SCHEMBL697034 | 0.82 | ALDH1A1 (0.35) | ALDH1A1MAPTTDP1KMT2AFPR2 | |
| SCHEMBL697333 | 0.81 | KMT2A (0.36) | ALDH1A1MAPTKMT2AFPR2SMN1; SMN2 | |
| SCHEMBL702874 | 0.80 | KMT2A (0.36) | ALDH1A1MAPTTDP1KMT2AFPR2 | |
| SCHEMBL697282 | 0.80 | P2RX7 (0.40) | ALDH1A1MAPTKMT2A | |
| SCHEMBL698829 | 0.79 | NPC1 (0.39) | TDP1KMT2ASMN1; SMN2 | |
| SCHEMBL698625 | 0.79 | MEN1 (0.37) | ALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL696990 | 0.79 | SMN1; SMN2 (0.35) | ALDH1A1TDP1KMT2AFPR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| EP-1981853-B1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ALDH1A1 617/4885MAPT 316/4885TDP1 2820/4885 |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ALDH1A1 617/4885MAPT 316/4885TDP1 2820/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ALDH1A1 617/4885MAPT 316/4885TDP1 2820/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ALDH1A1 617/4885MAPT 316/4885TDP1 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.